<DOC>
	<DOCNO>NCT01461018</DOCNO>
	<brief_summary>The purpose study ass long-term efficacy , tolerability , safety IgPro20 subject primary immunodeficiency ( PID ) extension precede follow-up study ZLB07_001CR ( NCT01458171 ) .</brief_summary>
	<brief_title>Multicenter Study Long-Term Clinical Outcomes Subcutaneous Immune Globulin IgPro20 Subjects With Primary Immunodeficiency ( Japan Study )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subjects complete precede followup study ZLB07_001CR . Written inform consent subject/parent/legally acceptable representative . Written assent underage subject ( â‰¥7 year &lt; 20 year age time obtain informed consent ) , accord competency subject . Pregnancy nurse mother . Participation study investigational medicinal product ( IMP ) within 3 month prior enrollment except study ZLB07_001CR . Subjects plan donate blood study . Known suspect antibody IMP , excipients IMP . Treatment another immunoglobulin G ( IgG ) within 3 month prior study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Immune globulin subcutaneous</keyword>
	<keyword>SCIG</keyword>
	<keyword>Primary immunodeficiency</keyword>
	<keyword>PID</keyword>
</DOC>